BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 11397835)

  • 1. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH.
    Tan SL; Farhi J; Homburg R; Jacobs HS
    Obstet Gynecol; 1996 Aug; 88(2):221-6. PubMed ID: 8692506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea.
    Martin KA; Hall JE; Adams JM; Crowley WF
    J Clin Endocrinol Metab; 1993 Jul; 77(1):125-9. PubMed ID: 8325934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.
    Corenthal L; Von Hagen S; Larkins D; Ibrahim J; Santoro N
    Fertil Steril; 1994 Jun; 61(6):1027-33. PubMed ID: 8194612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
    Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
    Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
    J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles.
    Filicori M; Flamigni C; Dellai P; Cognigni G; Michelacci L; Arnone R; Sambataro M; Falbo A
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1215-20. PubMed ID: 7962297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction.
    Filicori M; Flamigni C; Cognigni G; Dellai P; Michelacci L; Arnone R
    Fertil Steril; 1994 Aug; 62(2):279-85. PubMed ID: 8034073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.
    Fulghesu AM; Ciampelli M; Belosi C; Apa R; Guido M; Caruso A; Mancuso S; Lanzone A
    J Endocrinol Invest; 2001; 24(7):483-90. PubMed ID: 11508781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.